Princeton Satellite Systems (United States)

The behavioural tendency to expand sleep opportunity to compensate for prior sleep loss is referred to as 'sleep extension.' It is believed that sleep extension (here referred to as 'sleep opportunity extension' [SOE]) is the primary perpetuating factor explaining the transition from acute to chronic insomnia. Recently, this proposition was prospectively evaluated by assessing how sleep opportunity varied, week-by-week, relative to the incidence of acute and chronic insomnia. Significant differences in sleep opportunity before and after onset of acute insomnia were not detected. In the present analysis, a more granular evaluation was undertaken to assess whether SOE occurs on the nights and/or weekends following poor sleep. The data set (n = 1243) was modelled by group (good sleepers and participants with acute insomnia) for SOE occurring on the nights and weekends following poor nights of sleep (i.e., ≥ 30 min of sleep latency and/or nocturnal wakefulness and/or early morning awakenings) for the post-acute insomnia interval. A linear mixed effects model was used to account for up to one year of night-to-night sleep per participant. During the weekdays, sleep opportunity following a poor night of sleep was not found to increase (overall or by group) (< 5 min). During the weekends, all groups tended to decrease their sleep opportunity. This counterintuitive finding casts further doubt on the proposition that SOE is responsible for the transition between acute insomnia and chronic insomnia. This finding does not, however, change the relevance of addressing the mismatch between sleep opportunity and ability as part of behavioural treatment.

Sitta pusilla (Brown-headed Nuthatch) is a songbird of southeastern US pinelands. Since the first New Jersey sighting of the species in 2005, it has been recorded with increasing frequency in the state but had not been found breeding there. I found 2 nesting pairs in Cape May County in 2024 that both successfully fledged young. Further field work could determine if this is an outlier range spillover into uniquely suitable habitat or if the species is expanding further into New Jersey.

Introduction &amp; Objective: Use of branded anti-obesity medications (bAOMs) has increased concurrently with the rise of telemedicine, a convenient, cost-effective modality for patient care. However, limited data exist regarding characteristics of telemedicine users in medical weight management. This study examines the profile and treatment course of patients prescribed bAOMs for overweight or obesity via telemedicine at an academic weight center in New York City. Methods: This is a retrospective observational study of patients who started telemedicine treatment between May 1, 2020, and September 30, 2022, received a bAOM prescription (Contrave®, Qsymia®, Saxenda®, or Wegovy®), and had ≥6 (±2) months’ follow-up. Data were abstracted by electronic medical record query using relevant ICD/diagnosis codes and biomarker data to curate a dataset of eligible patients for analysis. Results: Patients who met inclusion criteria (N=1286) had a mean age of 47.2 (SD=12.8) years, initial weight of 220.9 (50.6) lb (n=934), initial BMI of 35.2 (6.5) (n=930), and an average of 2.2 weight-related comorbidities (most commonly dyslipidemia [n=705], hypertension [n=355], and prediabetes [n=595]). Most patients identified as White (63.7%); 72.2% of patients were female. Patients had a mean (SD) of 9.5 (7.2) telemedicine visits with physicians, nurse practitioners, and registered dietitians over 17.7 (7.2) months; 36.2% used both telemedicine and in-person visits, and 63.8% used only telemedicine. The most frequently prescribed bAOM was Wegovy® (70.3% of patients), followed by Saxenda® (17.6%), Contrave® (13.6%), and Qsymia® (12.4%). Conclusion: In this study, Wegovy® was the most commonly prescribed bAOM, and telemedicine facilitated frequent appointments (every 1.9 months on average). Future research is necessary to examine the impact of this treatment model on obesity and obesity-related comorbidities. Disclosure A. Shukla: Research Support; Eli Lilly and Company, Novo Nordisk. Consultant; Sun Pharmaceutical Industries Ltd. D. Li: None. A.J. Casper: None. L. Aronne: Advisory Panel; Novo Nordisk. Consultant; Novo Nordisk. Advisory Panel; Lilly Diabetes, Altimmune Inc. Consultant; Lilly Diabetes. Advisory Panel; Pfizer Inc. Consultant; UnitedHealth Group. Advisory Panel; Boehringer-Ingelheim. Board Member; AstraZeneca. Advisory Panel; Amgen Inc. D. D'Angelo: None. K.H. Saunders: Other Relationship; Intellihealth. L.I. Igel: Consultant; Novo Nordisk. Employee; Intellihealth. E. Lucas: Consultant; Intellihealth. K. Palepu: None. E. Zacherle: Employee; Novo Nordisk. A. Traina: Employee; Novo Nordisk. Stock/Shareholder; Novo Nordisk. K. Olsson: Employee; Novo Nordisk.

Pattern recognition in images is a classic application of neural nets. This chapter builds upon the previous one by exploring multilayer networks, which fall into the Machine Learning branch of our Autonomous Learning taxonomy. In this case, we will look at images of computer-generated digits and the problem of identifying the digits correctly. These images will represent numbers from scanned documents. Attempting to capture the variation in digits with algorithmic rules, considering fonts and other factors, quickly becomes impossibly complex, but with a large number of examples, a neural net can readily perform the task. We allow the weights in the net to perform the job of inferring rules about how each digit may be shaped, rather than codifying them explicitly.

One of the issues with machine learning is understanding the algorithms and why an algorithm made a particular decision. In addition, you want to be able to easily understand the decision. MATLAB has extensive graphics facilities that can be harnessed for that purpose. Plotting is used extensively in machine learning problems. MATLAB plots can be two- or three-dimensional. MATLAB also has many plot types such as line plots, bar charts, and pie charts. Different types of plots are better at conveying particular types of data. MATLAB also has extensive surface and contour plotting capabilities that can be used to display complex data in an easy-to-grasp fashion. Another facility is 3D modeling. You can draw animated objects, such as robots or automobiles. These are particularly valuable when your machine learning involves simulations.

Longitudinal control is the control about the pitch axis of an aircraft, it needs to work at all altitudes and speeds. In this chapter, we will implement a neural net to produce the critical parameters for a nonlinear aircraft control system. This is an example of online learning and applies techniques from multiple previous chapters.

The activity of protein phosphatase 2A (PP2A), a serine-threonine phosphatase, is reduced in the lung fibroblasts of idiopathic pulmonary fibrosis (IPF) patients. The objective of this study was to determine whether the reactivation of PP2A could reduce fibrosis and preserve the pulmonary function in a bleomycin (BLM) mouse model. Here, we present a new class of direct small-molecule PP2A activators, diarylmethyl-pyran-sulfonamide, exemplified by ATUX-1215. ATUX-1215 has improved metabolic stability and bioavailability compared to our previously described PP2A activators. Primary human lung fibroblasts were exposed to ATUX-1215 and an older generation PP2A activator in combination with TGFβ. ATUX-1215 treatment enhanced the PP2A activity, reduced the phosphorylation of ERK and JNK, and reduced the TGFβ-induced expression of ACTA2, FN1, COL1A1, and COL3A1. C57BL/6J mice were administered 5 mg/kg ATUX-1215 daily following intratracheal instillation of BLM. Three weeks later, forced oscillation and expiratory measurements were performed using the Scireq Flexivent System. ATUX-1215 prevented BLM-induced lung physiology changes, including the preservation of normal PV loop, compliance, tissue elastance, and forced vital capacity. PP2A activity was enhanced with ATUX-1215 and reduced collagen deposition within the lungs. ATUX-1215 also prevented the BLM induction of Acta2, Ccn2, and Fn1 gene expression. Treatment with ATUX-1215 reduced the phosphorylation of ERK, p38, JNK, and Akt and the secretion of IL-12p70, GM-CSF, and IL1α in BLM-treated animals. Delayed treatment with ATUX-1215 was also observed to slow the progression of lung fibrosis. In conclusion, our study indicates that the decrease in PP2A activity, which occurs in fibroblasts from the lungs of IPF subjects, could be restored with ATUX-1215 administration as an antifibrotic agent.

This paper discusses a system for Titan exploration enabled by nuclear fusion power. Titan is one of the most interesting locations in the solar system with a thick atmosphere, surface oceans, under-ice oceans and complex terrain. This paper provides a conceptual design of a fusion-powered system to explore many parts of Titan and enable the use of high-power instruments. The design includes a fusion-powered orbital transfer vehicle and an electric Titan science aircraft. A Direct Fusion Drive (DFD) propulsive engine could bring a sizable spacecraft to Titan orbit in less than two years. A second fusion reactor, configured as a closed-loop power generator, would be used for an electric Titan science aircraft. Both reactors are based on the Princeton Field-Reversed Configuration (PFRC) concept which combines an FRC with a magnetic mirror. PFRC uses a novel radio-frequency plasma heating system and deuterium-helium-3 fuel. A lower temperature plasma flows around the closed-field FRC region removing the fusion products. In the DFD propulsive configuration, this secondary flow permits direct and variable thrust and exhaust velocity. The science aircraft would do a powered entry to Titan and then have the capability to fly anywhere on the moon at subsonic speeds. The DFD-powered transfer vehicle would allow the in-orbit transfer stage to change inclination as needed to cover different areas of the surface.